Business Context and Reporting Period
Company: Werewolf Therapeutics, Inc. (Nasdaq: HOWL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Werewolf is an innovative biopharmaceutical company developing therapeutics engineered to stimulate the immune system for cancer treatment using its proprietary PREDATOR platform. The company has no products approved for commercial sale and has not generated revenue from product sales. Its primary focus is the clinical development of WTX-124 (IL-2 INDUKINE) and WTX-330 (IL-12 INDUKINE).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $1,885 |
| Net Loss | $(17,982) | $(36,071) | $(33,442) |
| Net Loss Per Share (Basic/Diluted) | $(0.40) | $(0.80) | $(0.79) |
| Operating Expenses | $17,542 | $35,533 | $38,007 |
| Cash and Cash Equivalents (Balance Sheet) | $77,596 (as of June 30, 2025) | ||
| Restricted Cash | $895 (as of June 30, 2025) | ||
| Total Debt (Note Payable) | $27,105 (Net carrying amount) | ||
| Accumulated Deficit | $(450,659) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue: Revenue was $0 for the six months ended June 30, 2025, compared to $1.9 million in the prior year period. This decrease is due to the completion of performance obligations under the Collaboration Agreement with Jazz Pharmaceuticals in June 2024, after which no further revenue was recognized.
- Net Loss: Net loss increased to $36.1 million for the six months ended June 30, 2025, from $33.4 million in the prior year period. The increase was driven by higher interest expense and lower interest income, partially offset by a decrease in operating expenses.
- Operating Expenses: Total operating expenses decreased by $2.5 million year-over-year to $35.5 million.
- R&D Expenses: Decreased by $1.9 million to $26.3 million, primarily due to reduced manufacturing costs for WTX-330 and JZP898, offset by increased clinical trial costs for WTX-124.
- G&A Expenses: Decreased by $0.6 million to $9.3 million, driven by lower personnel costs related to stock-based compensation timing.
- Interest Expense: Increased to $2.6 million from $2.1 million due to the higher effective interest rate on the K2HV Loan Agreement compared to the previous PWB Loan Agreement.
- Other Income: Other income, net decreased significantly to $0.2 million from $1.6 million, reflecting a smaller gain on the change in fair value of the derivative liability associated with the term loan.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: As of June 30, 2025, the company held $77.6 million in cash and cash equivalents. Management believes this is sufficient to fund operations into the fourth quarter of 2026. However, the company expects to incur substantial losses for the foreseeable future and will require additional funding to complete the development of WTX-124 and WTX-330.
- Debt Obligations: The company has a $30.0 million term loan with K2 HealthVentures (K2HV) maturing in May 2028. A third tranche of up to $10.0 million expired on June 30, 2025, without being drawn. A fourth tranche of up to $20.0 million remains available subject to lender discretion. The loan bears a variable interest rate (minimum 10.3%) and includes a 6.95% final fee.
- ATM Offering: The company is subject to the "Baby Shelf Limitation" under Form S-3, restricting its ability to sell more than $12.5 million in aggregate offering price. During the six months ended June 30, 2025, it sold 421,766 shares for net proceeds of $0.3 million.
- Key Risks:
- Development Risk: The company is early-stage with no approved products. Success depends on the clinical performance of WTX-124 and WTX-330.
- Manufacturing Risk: Reliance on third-party manufacturers for novel multi-domain biologics (INDUKINE/INDUCER) presents scaling and quality risks.
- Regulatory Risk: Potential disruptions at the FDA due to workforce reductions and budget cuts announced in early 2025 could delay reviews.
- Intellectual Property: Reliance on licensed technology from Harpoon Therapeutics and the need to defend patent rights.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that $77.6 million in cash will sustain operations through Q4 2026, given the high burn rate (~$34M operating cash outflow in H1 2025).
- Debt Covenants: Review the K2HV Loan Agreement covenants to ensure compliance, particularly regarding the pledge of assets and restrictions on additional indebtedness.
- ATM Capacity: Monitor the remaining capacity under the "Baby Shelf Limitation" ($12.5 million cap) and the company's ability to raise capital given the low stock price volatility.
- Clinical Milestones: Track the progress of the Phase 1/1b trial for WTX-124 and the Phase 1b/2 trial for WTX-330, as these are critical for future funding and potential milestone payments from Jazz.
- Derivative Liability: Monitor the fair value of the embedded derivative in the K2HV loan, as fluctuations in stock price can create non-cash gains or losses impacting the net loss.